AI assistant
Syngene International Limited — Call Transcript 2024
Jul 19, 2024
61231_rns_2024-07-19_8cc80b25-0740-4293-820c-ffb6b91a45a6.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [106 x 27] intentionally omitted <==
Ref: Syn/CS/SE/Reg 30/2024-25/Jul/07
July 19, 2024
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India
T +91 80 6891 8000 F +91 80 6775 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, To, The Manager, The Manager, BSE Limited National Stock Exchange of India Limited Corporate Relationship Department Corporate Communication Department Dalal Street, Mumbai – 400 001 Bandra (EAST), Mumbai – 400 051 Scrip Code: 539268 Scrip Symbol: SYNGENE
Dear Sir/Madam,
Subject: Intimation of Conference Call for Analysts and Investors
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the intimation for conference call for Analysts and Investors to be held on Thursday, July 25, 2024.
The above-mentioned information will also be available on website of the Company www.syngeneintl.com.
Request to kindly take this intimation on record.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
PRIYADARSHINI Digitally signed by PRIYADARSHINI MAHAPATRA DN: c=IN, postalCode=751015, st=ODISHA, street=ODISHA, l=KHORDA, o=Personal, serialNumber=df67e39aa5435d22f718c22d0516d97afb1208536f4f1860285e06c72d MAHAPATRA 0c9992, pseudonym=e816ac07281c470d84b50aab1b7bf795, 2.5.4.20=3b3032863a60d6cf503dc962d0b81de07d5cef26229a00b5f723a1ef57ab0005, [email protected], cn=PRIYADARSHINI MAHAPATRA Date: 2024.07.19 19:40:24 +05'30'
______ Priyadarshini Mahapatra
Head Legal, Company Secretary & Compliance Officer
INVESTOR CONFERENCE CALL INVITE
Q1 FY 2024-25
==> picture [594 x 151] intentionally omitted <==
Syngene’s Q1 FY2025 Results Conference Call
At 2:15 pm IST on 25[th] July 2024
The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Thursday, 25[th] July 2024 at 2.15 pm IST following the announcement of financial results for the quarter ended June 30, 2024.
The call will be initiated with a brief management discussion on the Q1 FY2025 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene’s Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.
Details of the conference call are as under:
| Date: | Thursday, 25th July 2024 |
|---|---|
| Time: | 2:15 pm to 3:00 pm IST |
| Dial-in Numbers* | |
| Primary Number | +91 22 6280 1279 / 91 22 7115 8180 |
| International Numbers | USA – 18667462133 UK – 08081011573 Singapore – 8001012045 Hong Kong – 800964448 Australia – 1800053698 |
| Pre-registration Facility (Diamond_Pass_™link) |
Step 1: Pre-register here .You will receive a passcode and a pin for the call on the registered email address. Step 2: Dial into the call on the Conference Call date, enter the passcode & pin as prompted. You will be directly connected to the call |
*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time
Syngene International: Putting Science to Work
Page 1
INVESTOR CONFERENCE CALL INVITE
Q1 FY 2024-25
==> picture [594 x 151] intentionally omitted <==
Replay/Audio Facility Dial in numbers: +91 22 71945757 Playback ID: 61549 The replay facility will be available from 25th July 2024 till 01 August 2024 The audio facility will also be available on the corporate website: https://syngeneintl.com/ Conference Call Transcript Will be available within 7 working days of the call on the corporate website: https://syngeneintl.com/
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com. For the Company’s latest Environmental, Social, and Governance (ESG) report, visit https://esgreport.syngeneintl.com/
For further information, please contact:
Krishnan G / Nandini Agarwal P: +91 80 6891 9807 M: +919819992927 / 7838382527 E: [email protected] E: [email protected]
Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forwardlooking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.
Syngene International: Putting Science to Work
Page 2